Endo’s Oxymorphone Solid Tablet Could Be Unscathed By Palladone Withdrawal

Purdue’s withdrawal of its opiate Palladone may not impact Endo’s pending oxymorphone product because of formulation differences, the company says. Endo hopes to avoid marketing restrictions for oxymorphone based on a broad clinical development program.